drugset / Trial / NCT02698280

Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma

NCT02698280 ↗

Phase 2 Completed 23 enrolled Huashan Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.

Timeline

Start
2015-07
Primary completion
2018-01
Completion
2018-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 5 mg/kg Intravenous
Subject Nimustine Small molecule 90 mg/m2 Intravenous
Subject Nimustine Small molecule 110 mg/m2 Intravenous

Indications